Device Trial Radar · NCT06533163
Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial
Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 17, 2025
Primary completion
Nov 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- BioTex, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical investigation is a non-randomized, multicenter, open-label, prospective, exposure-time escalation clinical investigation. The clinical investigation is designed to assess the clinical safety and performance of the Oncomagnetic Device.
Conditions
- Glioblastoma Multiforme
Interventions
Oncomagnetic deviceDevice
OncoMAGNETX has developed a portable wearable noninvasive magnetic device (Oncomagnetic device) for the treatment of GBM.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety of the Oncomagnetic device.Time frame: 6 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Medical Center Mannheim
Mannheim, Germany · Recruiting
Clinical Center Stuttgart
Stuttgart, Baden-Wurttemberg, Germany · Recruiting
Technical University of Munich
München, Bavaria, Germany · Recruiting
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.